FDA Committee Unanimously Recommends Egrifta for Lipodystrophy
FROM POZ.COM May 27, 2010 FDA Committee Unanimously Recommends Egrifta for Lipodystrophy A U.S. Food and Drug Administration (FDA) advisory committee has unanimously recommended that Egrifta (tesamorelin), Montreal-based Theratechnologies’ experimental product for the treatment of excess abdominal fat in HIV-positive people with lipodystrophy, be approved by the agency. Though the FDA is not required to …
FDA Committee Unanimously Recommends Egrifta for Lipodystrophy Read More »